RELEASING IN FULL

PAGE 01
BRASIL 12466 01 OF 06 072102Z
ACTION STR-17

INFO LOG-00 COFY-01 ADS-00 INR-10 SS-00 EB-08 ARA-00
SSO-00 L-03 INRE-00 OBS-09 JUSE-00 SP-02 /050 W
----------376371 072245Z /61

O 071724Z NOV 86
FM AMBASSADORA BRASILIA
TO SECSTATE WASHDC IMMEDIATE 0793
INFO USDOC WASHDC IMMEDIATE
AMCONSUL RIO DE JANEIRO
AMCONSUL SAO PAULO
AMCONSUL PORTO ALEGRE POUCH
AMCONSUL RECIFE POUCH
AMCONSUL SALVADOR DA BAHIA POUCH

CONFIDENTIAL SECTION 01 OF 06 BRASILIA 12466

USTR FOR JON ROSENBAUM AND CHRISTINA LUND

USDOC FOR 4330/IIP/WH/OSA/PETER FIELD AND
4300/IIP/WH/DAS/ANN HUGHES

E.O. 12356: DECL: OADC
TAGS: ETRD, EINV, PREL
SUBJECT: PHARMACEUTICAL CONSULTATIONS: SOME THOUGHTS
ABOUT THE ISSUES

REF:
(A) SAO PAULO 1776
(B) SAO PAULO 1560
(C) BRASILIA 3291
(D) BRASILIA 8229
(E) SAO PAULO 0472
(F) SAO PAULO 2672 (NOTAL)
(G) RIO DE JANEIRO 4707 (NOTAL)

1. CONFIDENTIAL - ENTIRE TEXT

CONFIDENTIAL

PAGE 02
BRASIL 12466 01 OF 06 072102Z

2. INTRODUCTION AND SUMMARY. THIS MESSAGE SETS OUT

Current Class: CONFIDENTIAL

UNITED STATES DEPARTMENT OF STATE
REVIEW AUTHORITY: NORMAN M. BOUTON
DATE/CASE ID: 19 DEC 2001 200000143

UNCLASSIFIED

3. THE MISSION BELIEVES THIS MEETING WILL BE LARGELY AN INFORMATION GATHERING EXERCISE. THE GOB WILL SEEK A BETTER INDICATION OF OUR CONCERNS, DOCUMENTATION AND DEMANDS. THE GOB IS UNLIKELY TO GO BEYOND EXISTING POSITIONS AT THIS MEETING. WE BELIEVE WE SHOULD USE THIS ENCOUNTER TO CLARIFY THE DIRECTIONS OF FUTURE GOB PHARMACEUTICAL POLICY, DEFINE OUR CONCERNS, EXPLORER PROBLEMS, AND ESTABLISH BENCHMARKS THAT THE GOB CAN USE TO EVALUATE OUR REACTION TO FUTURE GOB POLICY INITIATIVES.

4. WE HAVE INDICATED WE WISH THE CONSULTATIONS TO FOCUS ON PATENT PROTECTION, PROFITABILITY (PRICES), REGISTRATION AND FUTURE POLICY. WE BELIEVE THE GOB WILL FIND MOVEMENT ON PATENT PROTECTION DIFFICULT; OUR

ARGUMENTS WILL BE MOST EFFECTIVE IF WE CAN DOCUMENT THE OPPORTUNITY COSTS OF NO PROTECTION. ON PRICES, WE SHOULD PRESS FOR INDIRECT RELIEF NOW WHILE INSISTING ON TRANSPARENCY AND NON-DISCRIMINATION IN PRICE-SETTING POLICIES WHEN THE CRUZADO PLAN IS MODIFIED. THE CONSULTATIONS SHOULD PUT PRESSURE ON THE GOB TO SPEED-UP REGISTRATION OF NEW AND REFORMULATED PRODUCTS; A USG OFFER OF POSITIVE COOPERATION IN THE PROCESS WOULD INCREASE THIS PRESSURE. ON SECTORAL POLICIES, WE SHOULD SEEK, AMONG OTHER THINGS, CLARIFICATION AS TO WHAT EXTENT AND HOW THE
GOB INTENDS TO PROMOTE ITS NATIONAL COMPANIES. WE FURTHER RECOMMEND CONTINUATION OF MULTILATERAL PRESSURES ON GOB PHARMACEUTICAL POLICIES. END INTRODUCTION AND SUMMARY.

-----

CLIMATE

-----

5. THE NOVEMBER 20 CONSULTATIONS WILL TAKE PLACE AGAINST A RICH BACKGROUND OF GOB DEFENSIVENESS, CONCERN, AND PREOCCUPATION WITH DOMESTIC PROBLEMS. OUR REQUEST FOR CONSULTATIONS HAS PROVOKED CONCERN. THE NATIONAL PHARMACEUTICAL INDUSTRY, THE NCCS, FEARS THAT A BETTER DEAL FOR THE MNCS AND ANTI-PIRACY MOVES WILL REDUCE THEIR LIMITED SHARE OF THE PHARMACEUTICAL MARKET. SOME GOB HEALTH OFFICIALS, SUCH AS DIMED’S SUELI ROZENFELD, SHARE THIS CONCERN. MINISTER OF INDUSTRY AND COMMERCE JOSE HUGO CASTELO BRANCO HAS STATED THAT BRAZIL DOES NOT INTEND A "MARKET RESERVE" IN PHARMACEUTICALS AND
FM AMBASSADY BRASILIA
TO SECSTATE WASHDC IMMEDIATE 0794
INFO USDOC WASHDC IMMEDIATE
AMCONSUL RIO DE JANEIRO
AMCONSUL SAO PAULO
AMCONSUL PORTO ALEGRE POUCH
AMCONSUL RECIFE POUCH
AMCONSUL SALVADOR DA BAHIA POUCH

C O N T I N U A T I O N S E C T I O N 02 OF 06 BRASILIA 12466

USTR FOR JON ROSENBRAUM AND CHRISTINA LUND
USDOC FOR 4330/ISP/WH/OSA/PETER FIELD AND
- 4300/ISP/WH/DAS/ANN HUGHES

E.O. 12356: DECL: CDR
TAGS: ETRD, EINV, PREL
SUBJECT: PHARMACEUTICAL CONSULTATIONS: SOME THOUGHTS

FINE CHEMICALS. OTHERS CHALLENGE THE COMPANIES’
ASSERTIONS OF DAMAGE. DOMESTICALLY, THE GOB WILL BE
PREOCCUPIED WITH DIGESTING POLITICALLY THE RESULTS OF
THE NOVEMBER 15 ELECTIONS AND THE WIDELY-EXPECTED
ADJUSTMENTS IN THE CRUZADO PLAN. OUR BILATERAL TRADE
AGENDA ALSO COMPLICATES GOB CONSIDERATIONS: THE
INFORMATICS PROBLEM; THE FOLLOW-UP TO THE PUNTA DEL
ESTE MINISTERIAL; THE USG REQUEST FOR CONSULTATIONS ON
VIDEO-CASSETTES; THE EXPECTED USG DECISIONS ON GSP
AND ORANGE JUICE.

CONFIDENTIAL

CONFIDENTIAL

PAGE 02 BRASIL 12456 02 OF 06 072103Z

6. THE CONSULTATIONS WILL TAKE PLACE AGAINST A BACK-
GROUND OF DIVERSE THINKING ON GOB INVOLVEMENT IN
PHARMACEUTICALS AND RELATED HEALTH CARE. INDUSTRY
SOURCES ALLEGED THAT CEME, AND ITS REGISTRATION AUTHORITY,
DIMED, ARE CONTROLLED BY ULTRA-LEFTISTS, DIRECTING
POLICIES ACCORDING TO THEIR PERSONAL IDEOLOGIES. THEY
OPPOSE THE PARTICIPATION OF FOR-PROFIT PRIVATE DRUG
COMPANIES IN THE BRAZILIAN MARKET AND ADVOCATE THAT
BASIC MEDICAL CARE BE FREELY AND EQUALLY ADMINISTERED
THROUGH A NATIONALIZED HEALTH SYSTEM. AS ARGUED BY

WILL BE IMPORTANT IN DETERMINING THE POSSIBILITIES FOR PROGRESS ON THE SPECIFIC ISSUES UPON WHICH THE CONSULTATIONS WILL FOCUS.

THE ISSUES

7. WE HAVE INDIcATED TO THE GOB THAT WE WISH TO DISCUSS FOUR SPECIFIC ISSUES: PATENT PROTECTION, INADEQUATE PROFITS (READ PRICES), REGISTRATION PROBLEMS, AND GOB INVESTMENT POLICIES. BELOW, WE OFFER SOME OBSERVATIONS ON THE SCOPE OF THE ISSUES, HOW WE MIGHT ADDRESS THEM, WHAT WE MIGHT SEEK TO OBTAIN, AND THE NATURE OF THE PROBABLE GOB RESPONSE. IN GENERAL, WE BELIEVE THE GOB WILL SEEK TO USE THIS MEETING TO GET A BETTER INDICATION OF OUR CONCERNS, OUR DOCUMENTATION, AND THE CHANGES WE DESIRE. THE GOB IS UNLIKELY TO GO BEYOND EXISTING POSITIONS AT THIS MEETING. NEVERTHELESS, WE BELIEVE THE CONSULTATIONS CAN SERVE TO CLARIFY...
AREAS OF CONCERN AND ESTABLISH BENCHMARKS THAT THE GOB CAN USE TO EVALUATE OUR POSSIBLE REACTION TO FUTURE POLICY CHANGES. WE SHOULD SEEK ALSO TO ESTABLISH A FRAMEWORK FOR FUTURE CONSULTATIONS.

---------------
PATENT PROTECTION
---------------

8. AT THE TOP OF OUR AGENDA IN THE PHARMACEUTICAL CONSULTATIONS WILL BE THE LEGAL DENIAL, CODIFIED IN ARTICLE 9 OF LAW 5772 OF DECEMBER 21, 1971, OF PATENT
PROTECTION FOR PHARMACEUTICAL AND CHEMICAL PRODUCTS. SOME MNCS REPORT SIGNIFICANT LOSSES BECAUSE OF WIDESPREAD PIRACY OF EASY-TO-COPY PRODUCT LINES. OTHERS CLAIM THIS IS NOT A MAJOR PROBLEM FOR THEIR PARTICULAR PRODUCT LINES. A PARTIAL SURVEY CONDUCTED BY CONGEN SAO PAULO OF 16 PHARMACEUTICAL FIRMS INDICATED THAT IT WOULD NOT BE UNREASONABLE TO ESTIMATE DAMAGES TO U.S. FIRMS DUE TO PIRACY AT 1 BILLION DOLLARS OVER A 10-YEAR PERIOD (REF B). WE UNDERSTAND THAT THE PMA IS CONDUCTING A MORE COMPLETE SURVEY OF THESE LOSSES.

HOPEFULLY THE RESULTS OF THE SURVEY AND THE METHODOLOGY EMPLOYED WILL BE AVAILABLE PRIOR TO CONSULTATIONS.

9. PROGRESS ON THE PATENT PROTECTION ISSUE WILL BE VERY DIFFICULT BECAUSE MANY OF BRAZIL'S 490 NATIONAL CAPITAL PHARMACEUTICAL COMPANIES (NCCS) BELIEVE PATENT PROTECTION WOULD THREATEN THEIR VERY SURVIVAL. EVEN REPRESENTATIVES OF LARGE NCCS, SUCH AS ACHE AND PARMASA, HAVE TOLD US BLUNTLY THAT THE LACK OF PATENT PROTECTION IS NECESSARY AND THIS SITUATION WILL CHANGE ONLY WHEN NATIONAL FIRMS ARE STRONGER. WHILE THE ARGUMENT THAT PIRACY LEADS TO STRONGER NATIONAL FIRMS IS AN OBVIOUS NON SEQUITUR, WE MUST BE AWARE THAT PATENT PROTECTION, AT LEAST IN THE MEDIUM-TERM, WOULD REDUCE THE NCC'S CURRENT 20 PERCENT SHARE OF THE PHARMACEUTICAL MARKET. IN ADDITION, PROGRESS WILL BE DIFFICULT BECAUSE PATENT PROTECTION RUNS CONTRARY TO THE INTERESTS OF THE FEDERAL MEDICAL CENTER (CEME). THE NEW HEAD OF CEME, MARTA NOBRECA MARTINEZ, WAS QUOTED BY THE OCTOBER 16 PRESS AS
ADMITTING, "THE PROGRAM OF NATIONALIZING ESSENTIAL MEDICINES IS POSSIBLE ONLY BECAUSE A PATENT REGIME DOES NOT EXIST IN BRAZIL".

10. WE CAN THINK OF SEVERAL LINES OF DEFENSE THAT THE GOB MIGHT EMPLOY TO STYMIE PROGRESS ON THIS ISSUE. A TIME-HONORED GOB DEFENSE IS THAT THE LACK OF PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IS NOT INCONSISTENT WITH INTERNATIONAL AGREEMENTS SIGNED BY THE GOB. THE GOB MIGHT POINT OUT (IF THE NUMBERS ARE RIGHT) THAT MOST LDCS DO NOT EXTEND PATENT PROTECTION TO PHARMACEUTICAL PRODUCTS. THE GOB MAY ALSO ARGUE THAT LACK OF PATENT PROTECTION HAS BEEN ON THE BOOKS FOR A

CONFIDENTIAL

PAGE 03  BRAZIL 12466 03 OF 06 072103Z

LONG PERIOD AND MOST MNCS HAVE FOUND WAYS TO ADAPT TO THIS REALITY. THE GOB MAY ALSO CONTEND THAT THE LACK OF PATENT PROTECTION HAS NOT DISCOURAGED FOREIGN INVESTMENT IN THE PHARMACEUTICAL SECTOR WHICH, ACCORDING TO GOB FIGURES, GREW FROM 292 MILLION DOLLARS IN DECEMBER 1975 TO 1.113 BILLION IN DECEMBER 1985. THE PHARMACEUTICAL SHARE OF TOTAL FOREIGN INVESTMENT DURING THIS PERIOD ACTUALLY ROSE SLIGHTLY -- FROM 4.0 TO 4.7 PERCENT. THE GOB MAY POINT OUT THAT FOREIGN COMPANIES (AT LEAST THEIR LOCAL SUBSIDIARIES) HAVE CONSISTENTLY RATED THE LACK OF PATENT PROTECTION AS OF SECONDARY IMPORTANCE TO THEIR OPERATIONS.

11. TO COUNTER THESE PROBABLE LINES OF ARGUMENT, IN ADDITION TO ESTIMATES ON DAMAGES, WE BELIEVE IT USEFUL TO PROVIDE DATA ON THE OPPORTUNITY COSTS ASSOCIATED WITH THE LACK OF PATENT PROTECTION. WHILE ADMITTEDLY DIFFICULT AND INEXACT, PERHAPS OUR BEST CHANCE FOR A GOB RE-EXAMINATION OF ITS POSITION ON THE PATENT ISSUE IS TO CONVINCE THE GOB THAT THE FOREGONE INVESTMENTS, JOBS AND EXPORTS ARE SIZEABLE. WE WOULD ALSO RECOMMEND THE U.S., IN THE CONTEXT OF OUR GLOBAL CONCERNS ABOUT INADEQUATE PROTECTION OF INTELLECTUAL PROPERTY RIGHTS, CHALLENGE THE LACK OF PATENT PROTECTION FOR PHARMACEUTICALS/FINE CHEMICALS IN MULTILATERAL FORA SUCH AS GATT AND WIPO. WHILE ADMITTEDLY A LONG-TERM EFFORT, THIS MULTILATERAL PRESSURE WILL ENCOURAGE OTHER COUNTRIES TO EXAMINE THE GOB'S POLICIES.
INADEQUATE PROFITS
12. THE GOB HAS STRESSED THAT A REQUEST FOR SPECIAL TREATMENT ON PHARMACEUTICAL PRICES IS OUT OF THE QUESTION. SUCH TREATMENT WOULD VIOLATE THE GENERAL PRICE FREEZE INTRODUCED ON FEBRUARY 28 AS PART OF BRAZIL'S ECONOMIC STABILIZATION PROGRAM. THE PRICE FREEZE WILL NOT, HOWEVER, LAST FOREVER. PRICE ADJUSTMENTS WILL LIKELY BE A KEY PART OF THE MODIFICATIONS TO BE INTRODUCED AFTER THE NOVEMBER 15 ELECTIONS. NEVERTHELESS, WE SHOULD ADDRESS KEY PRICING POLICY ISSUES, AS WELL AS PRESS THE GOB TO PROVIDE

---

PRICE RELIEF IN THE SHORT TERM:


- -- REDUCED TARIFF LEVELS ON RAW MATERIAL INPUTS WOULD ALSO ALLEVIATE THE SECTOR'S PROBLEMS. IRONICALLY, IOF OR DUTY REDUCTIONS WOULD BENEFIT COMPANIES THAT ARE MOST IMPORT DEPENDENT. (FYI. WITH INCREASED CONSUMER DEMAND, REDUCED FINANCIAL COSTS AND A STRONGER CRUZADO, SOME AMERICAN PHARMACEUTICAL FIRMS ARE MAKING SOME OF THE BEST DOLLAR PROFITS IN YEARS. ON THE OTHER HAND, EUROPEAN MNCS ARE BEING SQUEEZED BY THEIR INCREASINGLY EXPENSIVE NON-DOLLAR DENOMINATED IMPORTS. END FYI.)

- -- IN THE MEDIUM-TERM (E.G., AS PART OF CRUZADO PLAN PRICE MODIFICATIONS), WE SHOULD PRESS FOR PHARMACEUTICAL PRICES ADJUSTMENTS TO BE AMONG THE LARGEST AND THE FIRST PRICE CHANGES. THE LEGITIMACY OF THE INDUSTRY'S 28 PERCENT INCREASE SCHEDULED FOR MARCH 1, WHICH WAS CANCELLED BY THE CRUZADO PLAN PRICE FREEZE, IS WIDELY CONCEIVED.
- -- WE MIGHT ALSO CONSIDER PUTTING FORWARD IDEAS ON HOW A POST-CRUZADO PRICING SYSTEM MIGHT WORK. FOR EXAMPLE, WOULD PHARMACEUTICAL COMPANIES AND THE GOB

CONSIDER THE PARTIAL DECONTROL OF PRICES FOR MEDICINES DESTINED LARGELY FOR MIDDLE-CLASS CONSUMPTION IN EXCHANGE FOR A COMMITMENT TO PROVIDE ESSENTIAL MEDICINES FOR LOW-INCOME GROUPS AT COST? THIS IDEA WAS EXPLORED BY THE COMPANIES WITH THE GOB SEVERAL YEARS AGO.

- -- A TRANSPARENT AND REVISED PRICING SYSTEM SHOULD BE AT THE TOP OF OUR PRIORITIES. WE NEED TO HAVE A CLEAR COMMITMENT FROM THE GOB THAT THE POST-CRUZADO PRICING MECHANISM WILL BE TRANSPARENT AND THAT ADEQUATE PROFITS ARE NECESSARY TO ENSURE THAT THE BRAZILIAN CONSUMER WILL HAVE ACCESS TO THE NEEDED MEDICINES. INADEQUATE PRICES MEAN INADEQUATE PROFITS, WHICH DAMAGE NCCS EVEN MORE THAN THE MNCs AND, THUS, BRAZIL'S GOAL OF DEVELOPING A STRONG NATIONAL INDUSTRY.

- -- WE SHOULD SEEK COMMENTS ON A NEW PRICING POLICY HAVING AS ITS OBJECTIVE SIMILAR PRICES FOR SIMILAR PRODUCTS. THE PRESENT COST STRUCTURE SUBMISSION PROCESS CREATES DISINCENTIVES FOR IMPROVING PRODUCTIVITY AND RESULTS IN WIDELY VARYING PRICES FOR IDENTICAL (OR VIRTUALLY IDENTICAL) DRUGS. (SEE PARA 2, REF E.)

13. THE GOB MAY ADMIT THAT PRICE DISCRIMINATION WAS FREQUENT IN THE PAST, BUT ARGUE THAT THE SARNEY GOVERNMENT HAS VIRTUALLY ELIMINATED THESE PRACTICES. FAR FROM RENDERING PAST DISCRIMINATION IRRELEVANT, THE CURRENT FREEZE HAS LOCKED IN THE EFFECTS OF PAST DISCRIMINATORY PRICING POLICIES. THEREFORE, IT IS APPROPRIATE TO PRESS THE GOB TO TAKE PAST DISCRIMINATION
INTO ACCOUNT WHEN PRICES ARE ADJUSTED. IT WOULD ALSO BE USEFUL TO DOCUMENT THE COSTS OF INADEQUATE PROFITS IN TERMS OF PRODUCT LINES WITHDRAWN FROM THE MARKET, COMPANIES THAT HAVE LEFT BRAZIL OVER THE PAST SEVERAL YEARS, AND LOST JOBS. WE MUST BE ABLE TO DOCUMENT PRICE DISCRIMINATION AGAINST U.S. MNCS AND TO
DEMONSTRATE THAT THIS DISCRIMINATION WAS NOT AN ISOLATED OR CASUAL PHENOMENON IN A COMPLEX SYSTEM.

14. THE REGISTRATION OF NEW MEDICINES, AND EVEN ROUTINE OR MINOR CHANGES, HAS SLOWED CONSIDERABLY SINCE THE BEGINNING OF THE SARNEY ADMINISTRATION. ACCORDING TO DIMED (GOB DRUG REGISTRATION ENTITY ROUGHLY EQUIVALENT TO THE FDA) FIGURES, DURING THE FIRST 9 MONTHS OF 1986, 4 NEW PRODUCTS WERE REGISTERED AND 160 ROUTINE PROCESSES WERE APPROVED. THESE APPROVAL FIGURES PALE WHEN COMPARED TO THE 3,600 OUTSTANDING PROCESSES -- RANGING FROM NEW PRESENTATIONS, NEW STRENGTHS, NEW DOSAGE FORMULAS AND IMPORT/EXPORT REQUESTS -- THAT ARE ON DIMED'S DOCKET. ON TOP OF THIS STAGGERING BACKLOG, DIMED RECEIVES ABOUT 20 NEW APPLICATIONS PER DAY. TO HANDLE THIS WORKLOAD, DIMED HAS ONLY SIX DOCTORS. DIMED'S DIRECTOR, SUELI ROZENFELD, HAS PUBLICLY ADMITTED THAT DIMED NEEDS TO INCREASE ITS STAFF "BY AT LEAST THREE TIMES". DIMED'S DIRECTOR ADMITS THAT THE REGISTRATION PROCESS IS SLOWER THAN IN THE PAST BUT ATTRIBUTES THE SLOWDOWN TO STRICTER REQUIREMENTS ON TECHNICAL DOCUMENTATION. INCREASED STRICTNESS ASIDE, IT IS ALSO TRUE THAT DIMED'S CURRENT ADMINISTRATION BELIEVES THAT THERE ARE TOO MANY PRODUCTS ON THE MARKET TODAY. WE SHOULD PRESS THE GOB TO INCREASE STAFF LEVELS ADEQUATE TO COMPLY WITH ITS MANDATED FUNCTIONS.

15. THE GOB IS LIKELY TO ARGUE THAT REGISTRATION OF NEW PRODUCTS TAKES NO LONGER IN BRAZIL THAN IN THE U.S. THE CHARGE THAT NCDC GETS FASTER TREATMENT AT DIMED THAN MNCS CAN BE COUNTERED BY THE ARGUMENT THAT IT IS THE MNCS WHICH INTRODUCE NEW TO MARKET
PRODUCTS WHICH MUST UNDERGO A CLOSER SCRUTINY THAN SIMPLE VARIATIONS ON KNOWN FORMULAS.

16. EMBASSY ONCE AGAIN REQUESTS WASHINGTON AGENCIES' COMMENTS ON WHETHER AND, IF SO, HOW THE FDA MIGHT COOPERATE WITH DIMED TO ASSIST IN IMPROVING EFFICIENCY AND TRANSPARENCY IN THE REGISTRATION PROCESS (REF C). A COOPERATIVE APPROACH TO DIMED'S PROBLEMS COULD TURN THIS PART OF THE CONSULTATIVE PROCESS IN A POSITIVE DIRECTION.

GOB PROGRAMS, PLANS AND THE ROLE OF FOREIGN INVESTMENT IN THE PHARMACEUTICALS/FINE CHEMICALS SECTOR

17. THE GOB'S INTENTIONS IN THE PHARMACEUTICAL/FINE CHEMICAL SECTOR REMAIN UNDEFINED. WHILE IT IS CLEAR THAT THE CONCEPT OF MARKET RESERVE IS SUPPORTED AT THE WORKING LEVEL IN SEVERAL KEY MINISTRIES, AND IN SOME SEGMENTS OF CONGRESS, WE DO NOT BELIEVE THE GOB WILL OPENLY ADOPT A MARKET RESERVE POLICY. IT IS CLEAR THAT MNCs CAN EXPECT LESS THAN NATIONAL TREATMENT FROM THE GOB IF THEIR EXPANSION PLANS CONFLICT WITH PLANS OF NATIONAL GROUPS. THE EXPERIENCES OF RHODIA AND CORNING ARE ILLUSTRATIVE OF HOW THE GOB CAN USE SEEMINGLY NEUTRAL PROGRAMS, SUCH AS PORTARIA IV, TO BENEFIT NCCs. WE MUST MAKE IT CLEAR TO THE GOB THAT NOT ADOPTING MARKET RESERVE FOR THE PHARMACEUTICAL/FINE CHEMICALS SECTOR IS NOT ENOUGH. FURTHER RESTRICTIONS AND A CONSOLIDATION OF NON-NATIONAL TREATMENT WOULD BE SUITABLE GROUNDS

CONFIDENTIAL
O 071724Z NOV 86
FM AMEMBASSY BRASILIA
TO SECSTATE WASHDC IMMEDIATE 0798
INFO USDOC WASHDC IMMEDIATE
AMCONSUL RIO DE JANEIRO
AMCONSUL SÃO PAULO
AMCONSUL PORTO ALEGRE POUCH
AMCONSUL RECIFE POUCH
AMCONSUL SALVADOR DA BAHIA POUCH

CONFIDENTIAL SECTION 06 OF 06 BRASILIA 12466

USTR FOR JON ROSENBAUM AND CHRISTINA LUND
USDOC FOR 4330/IEP/WH/OSA/PETER FIELD AND
- 4300/IEP/WH/DAS/ANN HUGHES

E.O. 12356: DECL: OADR
TAGS: ETRD, EINV, FREL
SUBJECT: PHARMACEUTICAL CONSULTATIONS: SOME THOUGHTS

TO JUDGE THE BRAZILIAN POLICIES AS UNFAIR, WARRANTING A STIFF REACTION FROM THE USG. WE CAN EXPECT THAT THE GOB WILL PRESS MNCS TO PRODUCE MORE RAW PRODUCTS IN BRAZIL.

18. THE GOB WILL ATTEMPT TO BE AS EVASIVE AS POSSIBLE ABOUT FUTURE PLANS. THE GOB MAY ARGUE THAT THE MNC SHARE OF THIS MARKET HAS INCREASED OVER TIME AND THAT THIS IS EVIDENCE THAT THE MNCSHAVE LEARNED HOW TO ADJUST TO THE BRAZILIAN REALITY. IT IS
IMPORTANT TO POINT OUT HOW THE UNCERTAINTY IN THE SECTOR, AND OTHER SECTORS, IMPAIRS NEEDED INVESTMENT AND TECHNOLOGY FLOWS.

19. THE INDUSTRIAL DEVELOPMENT COUNCIL (CDI), WHICH MUST APPROVE EXPANSIONS AND NEW INVESTMENTS IN THE PHARMACEUTICAL/FINE CHEMICALS AREA, MUST BE MADE ADMINISTRATIVELY RESPONSIBLE. CRITERIA FOR DECISION-MAKING MUST BE WRITTEN DOWN, FIXED DEADLINES FOR DECISIONS ARE NECESSARY AND A CLEAR AND EFFECTIVE APPEALS PROCEDURE IS NEEDED.

------------------

KEEPING THE PRESSURE ON

20. THE NOVEMBER 20 CONSULTATIONS ARE NOT LIKELY TO PRODUCE SUBSTANTIVE MOVEMENT ON THE ISSUES. HOWEVER, THE MEETING IS AN IMPORTANT FIRST STEP IN A LARGER AND LONGER PROCESS. OUR IMMEDIATE GOALS SHOULD INCLUDE:

- SETTING ANOTHER MEETING TO OBTAIN GOB RESPONSES TO OUR UNANSWERED QUESTIONS. WE COULD FOCUS THE GOB RESPONSE BY TABLEING A NON-PAPER DETAILING U.S. CONCERNS AT THE CONCLUSION OF THE CONSULTATIONS.

- OBTAINING AN AGREED MINUTE.

21. OVER THE LONGER RUN, THE NOVEMBER 20 CONSULTATIONS MAY ENCOURAGE OTHER GOVERNMENTS TO TAKE A MORE ACTIVE ROLE IN PRESSING THE GOB TO CLARIFY ITS POLICIES IN CONFIDENTIAL

THIS AREA. AT THE OCTOBER WEST GERMAN-BRAZILIAN BILATERAL CONSULTATIONS, THE FRG GOVERNMENT AND GERMAN BUSINESSMEN RAISED PHARMACEUTICAL/FINE CHEMICALS ISSUES AT GREAT LENGTH (SEPTEL). THESE CONSULTATIONS HIGHLIGHTED THE FACT THAT PHARMACEUTICAL/FINE CHEMICALS ISSUES ARE NOT SOLELY AN AMERICAN CONCERN. WE INTEND, THROUGH BRIEFINGS ON THE RESULTS OF OUR CONSULTATIONS, TO ENCOURAGE OTHER MAJOR INVESTORS
(I.E., U.K., HOLLAND, SWITZERLAND AND FRANCE) TO MAKE THEIR CONCERNS KNOWN TO THE GOB.

22. ADDITIONALLY, AS PART OF A LONGER TERM PROCESS, WE RECOMMEND THAT EFFORTS BEGIN IMMEDIATELY IN THE GATT TO CHALLENGE BRAZIL'S LAW OF SIMILARS (REF D). IF THE LAW OF SIMILARS IS ALLOWED TO STAND UNCHALLENGED, WE WILL REMAIN ON THE DEFENSIVE IN COMBATTING FURTHER RESTRICTIONS, NOT ONLY IN THE PHARMACEUTICAL/FINE CHEMICALS SECTORS, BUT IN OTHER SECTORS WHICH DRAW SIGNIFICANT INVESTMENTS FROM POWERFUL NATIONAL ECONOMIC GROUPS. ALSO, WE SHOULD UNDERTAKE TO STRENGTHEN THE SCOPE AND LENGTH OF PATENT PROTECTION IN WIPO AND GATT.

SHLAUDEMAN